Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.31 |
| ▸ | TSHR | P16473 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | MTOR | P42345 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.31 |
| ▸ | THPO | P40225 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6630569 | 0.92 | RIPK1 (0.45) | CA2RIPK1LMNAKCNH2KDM4E | |
| SCHEMBL27933551 | 0.84 | CA2 (0.36) | CA2SLC6A4SLC6A2 | |
| SCHEMBL21280529 | 0.84 | CA2 (0.37) | CA2RIPK1SLC6A4CYP2D6CYP1A2 | |
| SCHEMBL13871075 | 0.84 | RIPK1 (0.39) | CA2RIPK1SLC6A4CHRM1ADRA2B | |
| SCHEMBL5500512 | 0.83 | CA2 (0.41) | CA2RIPK1SLC6A4HTR2AHRH1 | |
| SCHEMBL8694969 | 0.81 | CA2 (0.49) | CA2HTR2ASIGMAR1 | |
| SCHEMBL14984000 | 0.80 | GSR (0.44) | CA2RIPK1SLC6A4LMNASLC6A2 | |
| SCHEMBL3386536 | 0.80 | TAAR1 (0.41) | CA2SLC6A4SLC6A2HTR2ASLC6A3 | |
| SCHEMBL3386613 | 0.80 | TAAR1 (0.41) | CA2SLC6A4SLC6A2HTR2ASLC6A3 | |
| SCHEMBL3386535 | 0.80 | TAAR1 (0.41) | CA2SLC6A4SLC6A2HTR2ASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275035-A1 | Nitroimidazole Compounds | JIRICEK JAN | 2008-11-06 | — | — | US | disclosed |
| US-7109229-B2 | Methods and compounds for treating proliferative diseases | ELI LILLY AND COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1325011-B1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | LILLY CO ELI (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040048915-A1 | Methods and compounds for treating proliferative diseases | ENGLER THOMAS ALBERT (US) | 2004-03-11 | — | — | US | disclosed |
| EP-1325011-A2 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002028861-A2 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048915-A1 | Methods and compounds for treating proliferative diseases | CDK4, CCNI, CCNA1 | CA2 4232/4885RIPK1 2996/4885SLC6A4 4731/4885 |
| US-20080275035-A1 | Nitroimidazole Compounds | NQO2, NQO1, MT-ND2 | CA2 3769/4885RIPK1 4520/4885SLC6A4 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.